HOGO

Hogo is a pre-clinical biotechnology company focused on the development of programmable antiviral therapeutics. Co-founded by CRISPR pioneers Feng Zhang, Omar Abudayyeh, and Jonathan Gootenberg, the company leverages RNA-guided systems, specifically Cas13, to target and degrade viral RNA within infected cells. This approach allows for the creation of sequence-specific medicines that can be rapidly reconfigured to address emerging viral threats and established pathogens. Hogo's platform aims to provide a broad-spectrum solution for pandemic preparedness and the treatment of high-impact respiratory infections. The company is headquartered in Cambridge, Massachusetts, and operates at the intersection of gene editing and infectious disease research.